Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|December 17, 2017
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancerPauline du Rusquec, Clément Palpacuer, Loic Campion, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETESégolène Hescot, Véronique Debien, Julien Hadoux, et al.
JCO Precision Oncology|January 7, 2022
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Grégoire Marret, Ivan Bièche, Célia Dupain, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2023
Accelerated subsequent lung cancer after post-operative radiotherapy for breast cancerClémence Basse, Julien Ancel, Marie-Ange Massiani, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 31, 2017
Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancerEric Voog, Loïc Campion, Pauline du Rusquec, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
NPJ Precision Oncology|December 15, 2025
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trialsFederico Nichetti, Jennifer Hüllein, Pauline du Rusquec, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2024
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU studyMarion Ferreira, Aurélie Swalduz, Laurent Greillier, et al.
Translational Lung Cancer Research|August 13, 2025
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile studyEdouard Auclin, Pauline Du Rusquec, Victor Albarran-Artahona, et al.
NPJ Precision Oncology|June 24, 2021
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trialIstvan Petak, Maud Kamal, Anna Dirner, et al.
Pageof 3